News | November 01, 2010

Boston Scientific to Sell Neurovascular Business

November 2, 2010 – Boston Scientific will sell its neurovascular business to Stryker for $1.5 billion in cash. Of that purchase price, $1.4 billion will be paid at closing, and the remaining $100 million will be paid upon commercialization of the Target Detachable Coils. Several manufacturing facilities will also be transferred to Stryker.

Boston Scientific’s neurovascular business develops less-invasive medical technologies used to treat brain aneurysms and other types pf cerebrovascular disease.

“We deeply appreciate the contributions of our neurovascular employees and wish them continued success going forward in this new venture,” said Ray Elliott, president and CEO of Boston Scientific. “We believe this transaction will prove to be a win-win for all parties.”

For more information: www.bostonscientific.com, www.stryker.com

Related Content

Corindus Seeking Neurovascular Intervention Clearance for CorPath GRX Vascular Robotic System
News | Stroke | February 15, 2019
Corindus Vascular Robotics Inc. is seeking premarket clearance from the U.S. Food and Drug Administration (FDA) to use...
NeuroLogica and MaxQ AI Announce Distribution Agreement
News | Stroke | November 30, 2018
Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement...
Medication Alone May Not Eliminate Stroke Risk in Carotid Atherosclerotic Stenosis Patients
News | Stroke | October 31, 2018
Recent statin and medication advances have led some researchers to suggest surgical treatments for carotid stenosis...
iSchemaView RAPID Technology Now Installed in More Than 500 Stroke Centers
News | Stroke | August 28, 2018
iSchemaView announced that more than 575 stroke centers in 22 countries have selected the RAPID advanced imaging...
Breast feeding may help reduce the stroke risk in women. Katherine Fornell

Breast feeding may help reduce the stroke risk in women.

News | Stroke | August 22, 2018
Breastfeeding is not only good for babies, according to new research in the Journal of the American Heart Association....
iSchemaView Brings RAPID Imaging Platform to Australia and New Zealand
News | Stroke | July 13, 2018
July 13, 2018 – iSchemaView has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAP
NewYork-Presbyterian Expands Mobile Stroke Treatment Unit Fleet
News | Stroke | June 11, 2018
NewYork-Presbyterian, in collaboration with Weill Cornell Medicine, Columbia University Irving Medical Center and the...
International Study Suggests Combination Therapy May Prevent Stroke in Certain People
News | Stroke | June 07, 2018
June 7, 2018 — Results from an international clinical trial show that combining...
The Vivistim device is similar to a pacemaker, which uses leads to electrically stimulate the brain. A new clinical trial at The Ohio State University Wexner Medical Center is examining use of this device for stroke rehabilitation.

A new clinical trial at The Ohio State University Wexner Medical Center is examining an implanted device that uses vagus nerve stimulation to help stroke patients regain motor function. The Vivistim device is similar to a pacemaker, which uses leads to electrically stimulate the brain. 

News | Stroke | May 09, 2018
May 9, 2018 — Stroke rehabilitation specialists at the The Ohio State University Wexner Medical Center are among the
Overlay Init